5.1(top 5%)
impact factor
1.4K(top 20%)
papers
54.9K(top 5%)
citations
104(top 5%)
h-index
5.2(top 5%)
impact factor
1.6K
all documents
59.4K
doc citations
162(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1The therapeutic monoclonal antibody marketMAbs20151,049
2The making of bispecific antibodiesMAbs2017626
3The immunogenicity of humanized and fully human antibodiesMAbs2010569
4Industrialization of mAb production technology: The bioprocessing industry at a crossroadsMAbs2009554
5Site-specific antibody drug conjugates for cancer therapyMAbs2014547
6Cell culture processes for monoclonal antibody productionMAbs2010540
7Recovery and purification process development for monoclonal antibody productionMAbs2010416
8Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myelomaMAbs2015405
9Antibodies to watch in 2019MAbs2019387
10Antibodies to watch in 2020MAbs2020381
11Antibody fragmentsMAbs2010370
12Dual targeting strategies with bispecific antibodiesMAbs2012362
13Charge variants in IgG1MAbs2010350
14Disulfide bond structures of IgG moleculesMAbs2012347
15Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugatesMAbs2016340
16Marketed therapeutic antibodies compendiumMAbs2012320
17Analytical methods for physicochemical characterization of antibody drug conjugatesMAbs2011298
18Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional propertiesMAbs2013280
19Phage display-derived human antibodies in clinical development and therapyMAbs2016263
20Bispecific antibodies for cancer therapyMAbs2009260
21Fragmentation of monoclonal antibodiesMAbs2011258
22Discovery and mechanism of ustekinumabMAbs2011246
23The impact of glycosylation on monoclonal antibody conformation and stabilityMAbs2011241
24Antibodies to watch in 2022MAbs2022239
25Antibodies to watch in 2021MAbs2021237
26Projecting human pharmacokinetics of therapeutic antibodies from nonclinical dataMAbs2011235
27Antibodies to watch in 2017MAbs2017225
28Macrophages are critical effectors of antibody therapies for cancerMAbs2015223
29Antibodies to watch in 2018MAbs2018223
30CatumaxomabMAbs2010218
31The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicityMAbs2018215
32Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor αMAbs2010214
33Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodiesMAbs2012214
34Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functionsMAbs2010213
35Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugatesMAbs2013213
36ABodyBuilder: Automated antibody structure prediction with data–driven accuracy estimationMAbs2016208
37Antibody-based therapeutics to watch in 2011MAbs2011207
38CanakinumabMAbs2010203
39Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodiesMAbs2010201
40A strategy for risk mitigation of antibodies with fast clearanceMAbs2012200
41Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originMAbs2009195
42Neonatal Fc receptor and IgG-based therapeuticsMAbs2011194
43Marketing approval of mogamulizumabMAbs2012193
44Human immunoglobulin allotypesMAbs2009187
45Structure, heterogeneity and developability assessment of therapeutic antibodiesMAbs2019186
46A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical propertiesMAbs2013183
47Antibody biodistribution coefficientsMAbs2013177
48Affinity of human IgG subclasses to mouse Fc gamma receptorsMAbs2017175
49Potential aggregation prone regions in biotherapeuticsMAbs2009173
50Physicochemical characterization of Remsima®MAbs2014173